Cadence Pharma boosts 4Q sales outlook for Ofirmev

SAN DIEGO (AP) -- Cadence Pharmaceuticals Inc. said Wednesday that it now expects fourth-quarter sales of its intravenous fever and pain treatment Ofirmev to total about $17.1 million, exceeding its previous projection.

The company previously predicted fourth-quarter Ofirmev sales of between $15.9 million and $16.4 million.

Ofirmev is an injectable version of the drug acetaminophen, the active ingredient in Tylenol.

For the full year, Cadence said it expects sales of the drug to total between $94 million and $100 million.

Shares of Cadence, which is based in San Diego, rose 7 cents to $5.07 in midday trading.